Levacetylleucine clinical trials
Also written N-Acetyl-L-Leucine and IB1001.
How each study uses levacetylleucine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the levacetylleucine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Sept 2024 · AQNEURSA · NDA 219132 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
IntraBio Inc (3)
Studies
Open first, then newest update. How each study uses levacetylleucine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type CRecruitingPhase 3IntraBio IncNCT05163288Written as N-Acetyl-L-Leucine
- A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)Active, not recruitingPhase 3IntraBio IncNCT06673056Written as N-Acetyl-L-Leucine
- Pivotal Study of N-acetyl-L-leucine for CACNA1AActive, not recruitingPhase 3IntraBio IncNCT07221292Written as N-Acetyl-L-Leucine
Codes
What other systems call levacetylleucine · ClinicalTrials.gg INT002112
- UNII (FDA) E915HL7K2OLEVACETYLLEUCINEOne source FDA
- NCI Thesaurus C211767LevacetylleucineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E915HL7K2O | LEVACETYLLEUCINE | One source FDA |
| NCI Thesaurus | C211767 | Levacetylleucine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.